Processa Pharmaceuticals, Inc. Common (PCSA)

Price$2.71

Favorite Metrics

Price vs S&P 500 (26W)-76.01%

Price vs S&P 500 (4W)24.13%

Market Capitalization$8.25M

All Metrics

Book Value / Share (Quarterly)$2.17

P/TBV (Annual)2.35x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.43

Price vs S&P 500 (YTD)3.50%

Gross Margin (TTM)32.24%

Net Profit Margin (TTM)-2981.25%

EPS (TTM)$-17.05

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-17.05

EPS (Annual)$-10.36

ROI (Annual)-243.20%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-3230.38%

Cash / Share (Quarterly)$2.15

ROA (Last FY)-173.59%

EBITD / Share (TTM)$-10.82

ROE (5Y Avg)-315.34%

Operating Margin (TTM)-2707.69%

Cash Flow / Share (Annual)$-4.43

P/B Ratio1.48x

P/B Ratio (Quarterly)1.17x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)32.56x

Net Interest Coverage (TTM)-54.45x

ROA (TTM)-191.11%

EPS Incl Extra (Annual)$-10.36

Current Ratio (Annual)2.54x

Quick Ratio (Quarterly)2.48x

3-Month Avg Trading Volume0.56M

52-Week Price Return-51.18%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.32

P/S Ratio (Annual)1649.22x

Asset Turnover (Annual)1.67x

52-Week High$19.63

Operating Margin (5Y Avg)-1796.65%

EPS Excl Extra (Annual)$-10.36

Tangible BV CAGR (5Y)82.09%

26-Week Price Return-67.27%

Quick Ratio (Annual)2.48x

13-Week Price Return-10.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.54x

Enterprise Value$2.709

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-41.76%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-6744.00%

Cash / Share (Annual)$2.15

3-Month Return Std Dev103.31%

Gross Margin (5Y Avg)39.43%

Net Income / Employee (TTM)$-1

ROE (Last FY)-243.20%

Net Interest Coverage (Annual)-54.47x

EPS Basic Excl Extra (Annual)$-10.36

Receivables Turnover (TTM)227.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-17.05

Receivables Turnover (Annual)226.80x

ROI (TTM)-257.70%

P/S Ratio (TTM)102.18x

Pretax Margin (5Y Avg)-3012.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.32

Price vs S&P 500 (52W)-86.28%

Year-to-Date Return7.64%

5-Day Price Return8.01%

EPS Normalized (Annual)$-10.36

ROA (5Y Avg)-218.81%

Net Profit Margin (Annual)-6720.00%

Month-to-Date Return22.77%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$-10.67

Operating Margin (Annual)-1336.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-314.79%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-17.05

P/TBV (Quarterly)2.35x

P/B Ratio (Annual)1.17x

Inventory Turnover (TTM)1.15x

Pretax Margin (TTM)-2978.85%

Book Value / Share (Annual)$2.17

Price vs S&P 500 (13W)-13.27%

Beta1.15x

Revenue / Share (TTM)$0.00

ROE (TTM)-257.81%

52-Week Low$1.76

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.00

4.14

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PCSAProcessa Pharmaceuticals, Inc. Common	102.18x	—	32.24%	—	$2.71
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.71
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.93x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Chemotherapy (NGC) oncology treatments by modifying how the body processes existing FDA-approved cancer drugs while maintaining their mechanism of action. The company's pipeline includes three NGC drug candidates: PCS6422 (NGC-Cap), PCS3117 (NGC-Gem), and PCS11T (NGC-Iri).